MHRA-100080-PIP01-21

Key Facts

Active Substance
Active Substance:
  • Anti-C1s Humanized IgG4 Monoclonal Antibody
Invented Name
Not yet available
PIP Number MHRA-100080-PIP01-21
Pharmaceutical form(s)
  • Solution for infusion
  • Solution for injection
Therapeutic area
  • Neurology
  • Immunology -Rheumatology-Transplantation
  • Haematology-Hemostaseology
Conditions / Indications
Conditions / Indications:
  • Treatment of Immune Thrombocytopenic Purpura
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Anti-C1s Humanized IgG4 Monoclonal Antibody.pdf
Published Date 17/12/2021